Summary: | Lymphoma is a cancer that begins in the lymphocyte cells of the immune system. There are over 60 different types, broadly grouped into Hodgkin lymphomas and non-Hodgkin lymphomas. Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of Non-Hodgkin lymphoma. The primary treatment for DLBCL is R-CHOP (Rituximab, Cyclophosphamide, doxorubicin hydrochloride (Hydroxy daunomycin), Oncovin, and Prednisone) chemotherapy. However, even after the treatment, only 50-60% of patients show complete response; the remaining patients suffer from progression in the form of relapse (cancer reappearing) and refractory disease (cancer stops responding to treatment).
|